EA201892541A1 - Гуманизированные анти-il-1r3 антитела - Google Patents
Гуманизированные анти-il-1r3 антителаInfo
- Publication number
- EA201892541A1 EA201892541A1 EA201892541A EA201892541A EA201892541A1 EA 201892541 A1 EA201892541 A1 EA 201892541A1 EA 201892541 A EA201892541 A EA 201892541A EA 201892541 A EA201892541 A EA 201892541A EA 201892541 A1 EA201892541 A1 EA 201892541A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- relates
- present
- antibodies
- antibody
- cancer
- Prior art date
Links
- 101000960952 Homo sapiens Interleukin-1 receptor accessory protein Proteins 0.000 abstract 5
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 abstract 5
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 abstract 1
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract 1
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract 1
- 108010082786 Interleukin-1alpha Proteins 0.000 abstract 1
- 102000017761 Interleukin-33 Human genes 0.000 abstract 1
- 108010067003 Interleukin-33 Proteins 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Настоящее изобретение относится к гуманизированным антителам, которые специфически связываются с IL-1R3, или их фрагментам или производным или полипептидам, содержащим по меньшей мере часть указанного антитела, которая является достаточной для обеспечения IL-1R3-связывающей специфичности. Указанные антитела подавляют индуцированную IL-1R3 активность NFκB. Они также подавляют активность NFκB, стимулированную IL-1-альфа, IL-1бета, IL-33 и/или IL-36. Настоящее изобретение также относится к применению гуманизированного антитела для лечения IL-1R3-опосредованного заболевания, такого как рак. Настоящее изобретение также относится к фармацевтической композиции, содержащей фармацевтически приемлемый носитель и терапевтически эффективное количество антитела по изобретению. Фармацевтическая композиция может быть использована для лечения IL-1R3-опосредованного заболевания, такого как рак.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16168617.5A EP3241845A1 (en) | 2016-05-06 | 2016-05-06 | Humanized anti-il-1r3 antibodies |
PCT/EP2017/060925 WO2017191325A1 (en) | 2016-05-06 | 2017-05-08 | Humanized anti-il-1r3 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201892541A1 true EA201892541A1 (ru) | 2019-03-29 |
Family
ID=55919721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201892541A EA201892541A1 (ru) | 2016-05-06 | 2017-05-08 | Гуманизированные анти-il-1r3 антитела |
Country Status (15)
Country | Link |
---|---|
US (2) | US11203642B2 (ru) |
EP (2) | EP3241845A1 (ru) |
JP (2) | JP7038462B2 (ru) |
KR (3) | KR20230107695A (ru) |
CN (3) | CN116178548A (ru) |
AU (1) | AU2017260399B2 (ru) |
BR (1) | BR112018072681A8 (ru) |
CA (1) | CA3022657A1 (ru) |
EA (1) | EA201892541A1 (ru) |
IL (2) | IL297527A (ru) |
MX (2) | MX2018013517A (ru) |
NZ (1) | NZ748130A (ru) |
SG (1) | SG11201809764XA (ru) |
WO (1) | WO2017191325A1 (ru) |
ZA (1) | ZA201807167B (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3055256A1 (en) * | 2017-03-09 | 2018-09-13 | Mab Discovery Gmbh | Antibodies specifically binding to human il-1r7 |
EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
JP2020527332A (ja) | 2017-06-12 | 2020-09-10 | ブルーフィン バイオメディシン, インコーポレイテッド | 抗−il1rap抗体および抗体薬物コンジュゲート |
TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商23與我有限公司 | 抗il1rap抗體及其使用方法 |
EP4211165A1 (en) | 2020-09-14 | 2023-07-19 | Ichnos Sciences SA | Antibodies that bind to il1rap and uses thereof |
EP4288457A2 (en) * | 2021-02-05 | 2023-12-13 | Boehringer Ingelheim International GmbH | Anti-il1rap antibodies |
JP2024520338A (ja) | 2021-05-21 | 2024-05-24 | レオ ファーマ アクティーゼルスカブ | 抗il-1受容体アクセサリータンパク質抗体 |
WO2024062074A1 (en) | 2022-09-21 | 2024-03-28 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5283179A (en) | 1990-09-10 | 1994-02-01 | Promega Corporation | Luciferase assay method |
DK0488470T3 (da) | 1990-11-26 | 1997-12-22 | Akzo Nobel Nv | Fremgangsmåde til fremstilling af antistoffer |
PE64396A1 (es) | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
US6974682B1 (en) | 1996-08-26 | 2005-12-13 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
EP0915987A2 (en) | 1997-04-21 | 1999-05-19 | Donlar Corporation | POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
US6280955B1 (en) | 1997-12-16 | 2001-08-28 | Tularik Inc. | Interleukin-1 receptor accessory proteins, nucleic acids and methods |
ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
US6541225B1 (en) | 2000-01-26 | 2003-04-01 | Raven Biotechnologies, Inc. | Methods and compositions for generating human monoclonal antibodies |
US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
US20030026806A1 (en) | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
US7049095B2 (en) | 2000-10-31 | 2006-05-23 | Immunex Corporation | DNA encoding IL-1 receptor accessory protein |
WO2003014309A2 (en) | 2001-08-07 | 2003-02-20 | Immunex Corporation | Interleukin-1 receptors in the treatment of diseases |
WO2003073238A2 (en) | 2002-02-27 | 2003-09-04 | California Institute Of Technology | Computational method for designing enzymes for incorporation of amino acid analogs into proteins |
US7438910B2 (en) | 2002-09-06 | 2008-10-21 | Amgen Inc. | Therapeutic human anti-IL1-R1 monoclonal antibody |
SG2013005590A (en) | 2003-01-22 | 2015-06-29 | Roche Glycart Ag | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
US20040224893A1 (en) | 2003-05-06 | 2004-11-11 | Li-Hsien Wang | Methods of using IL-1 antagonists to treat neointimal hyperplasia |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
JP4890253B2 (ja) | 2003-10-09 | 2012-03-07 | アンブレツクス・インコーポレイテツド | アジドまたはアセチレン末端水溶性ポリマー |
ME03330B (me) | 2003-11-05 | 2019-10-20 | Roche Glycart Ag | Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom |
BRPI0507236A (pt) | 2004-01-30 | 2007-06-26 | Peplin Biolipids Pty Ltd | método para o tratamento ou profilaxia de uma condição, e, composto |
US8778880B2 (en) | 2004-02-02 | 2014-07-15 | Ambrx, Inc. | Human growth hormone modified at position 35 |
US8945857B2 (en) | 2005-07-01 | 2015-02-03 | John Schrader | Methods of isolating cells and generating monoclonal antibodies |
SG192479A1 (en) | 2005-08-26 | 2013-08-30 | Roche Glycart Ag | Modified antigen binding molecules with altered cell signaling activity |
MX2008014692A (es) | 2006-05-19 | 2009-08-18 | Alder Biopharmaceuticals Inc | Metodo de cultivo para obtener una poblacion clonal de celulas b especificas de antigeno. |
US8709715B2 (en) | 2008-03-26 | 2014-04-29 | Cellerant Therapeutics, Inc. | Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof |
CA2755640C (en) | 2009-03-20 | 2018-05-22 | Genentech, Inc. | Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr |
GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
EP2556087A1 (en) | 2010-04-09 | 2013-02-13 | Novozymes Biopharma DK A/S | Albumin derivatives and variants |
DK2400298T3 (da) | 2010-05-28 | 2013-09-02 | Hoffmann La Roche | Enkelt B-celle-dyrkningsfremgangsmåde og specifik antistoffremstilling |
EP2665749B1 (en) | 2011-01-19 | 2016-01-13 | Cantargia AB | Anti-il1rap antibodies and their use for treating solid tumours |
JP2014519480A (ja) | 2011-04-15 | 2014-08-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌で使用される抗il−1r1阻害物質 |
WO2012177595A1 (en) * | 2011-06-21 | 2012-12-27 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
WO2013023015A2 (en) | 2011-08-11 | 2013-02-14 | Albert Einstein College Of Medicine Of Yeshiva University | Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes |
WO2014100772A1 (en) | 2012-12-21 | 2014-06-26 | Cellerant Therapeutics, Inc. | Antibodies that bind membrane-bound il1rap |
US10126304B2 (en) | 2013-01-16 | 2018-11-13 | George Mason Research Foundation, Inc. | Binding domain mapping |
GB201403875D0 (en) * | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
GB201413913D0 (en) * | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
AU2016282869B2 (en) | 2015-06-26 | 2022-08-18 | Sanofi Biotechnology SAS | Monoclonal anti-IL-1RAcP antibodies |
EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
-
2016
- 2016-05-06 EP EP16168617.5A patent/EP3241845A1/en not_active Withdrawn
-
2017
- 2017-05-08 AU AU2017260399A patent/AU2017260399B2/en active Active
- 2017-05-08 EP EP17724778.0A patent/EP3452513B1/en active Active
- 2017-05-08 SG SG11201809764XA patent/SG11201809764XA/en unknown
- 2017-05-08 IL IL297527A patent/IL297527A/en unknown
- 2017-05-08 US US16/099,059 patent/US11203642B2/en active Active
- 2017-05-08 KR KR1020237021882A patent/KR20230107695A/ko not_active Application Discontinuation
- 2017-05-08 IL IL262776A patent/IL262776B2/en unknown
- 2017-05-08 NZ NZ748130A patent/NZ748130A/en unknown
- 2017-05-08 EA EA201892541A patent/EA201892541A1/ru unknown
- 2017-05-08 CN CN202211533197.6A patent/CN116178548A/zh active Pending
- 2017-05-08 JP JP2019510473A patent/JP7038462B2/ja active Active
- 2017-05-08 KR KR1020227010275A patent/KR102550643B1/ko active IP Right Grant
- 2017-05-08 CA CA3022657A patent/CA3022657A1/en active Pending
- 2017-05-08 WO PCT/EP2017/060925 patent/WO2017191325A1/en active Application Filing
- 2017-05-08 CN CN201780041725.7A patent/CN109415442B/zh active Active
- 2017-05-08 BR BR112018072681A patent/BR112018072681A8/pt unknown
- 2017-05-08 CN CN202211533431.5A patent/CN116178549A/zh active Pending
- 2017-05-08 KR KR1020187034930A patent/KR102381257B1/ko active IP Right Grant
- 2017-05-08 MX MX2018013517A patent/MX2018013517A/es unknown
-
2018
- 2018-10-26 ZA ZA2018/07167A patent/ZA201807167B/en unknown
- 2018-11-05 MX MX2023002554A patent/MX2023002554A/es unknown
-
2021
- 2021-08-24 US US17/410,153 patent/US20220089751A1/en active Pending
-
2022
- 2022-03-03 JP JP2022032317A patent/JP7480199B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201892541A1 (ru) | Гуманизированные анти-il-1r3 антитела | |
EA201792522A1 (ru) | Лечение злокачественной опухоли с помощью комбинированной блокады сигнальных путей pd-1 и cxcr4 | |
EA201891178A1 (ru) | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения | |
MX2016001640A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
EA201692530A1 (ru) | Цитотоксические пептиды и их конъюгаты | |
EA201590144A1 (ru) | Rspo3-связывающие агенты и их применение | |
EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
EA201991214A1 (ru) | Антитела против pd-1 и их композиции | |
EA201690905A1 (ru) | Специфические антитела против cd38 для лечения злокачественных новообразований у человека | |
BR112015021115A2 (pt) | agentes para induzir apoptose para o tratamento de câncer e doenças imunes e autoimunes | |
EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
EA202091747A1 (ru) | Составы антитела b7-h4 | |
EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
EA202092420A1 (ru) | Антитело против pd-l1 и его применение | |
EA202190588A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
EA201990988A1 (ru) | Антитела против chikv и пути их применения | |
EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
EA201791933A1 (ru) | Ингибирование активности olig2 | |
EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
BR112016023011A2 (pt) | tratamento de câncer gástrico | |
EA201990508A1 (ru) | ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2 | |
EA202090945A1 (ru) | Анти-msln-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его | |
EA201991283A1 (ru) | Фармацевтическая композиция для предотвращения опиоидной зависимости | |
EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения |